- SimAbs has raised €5 million in a Series A funding round to expand its continuous manufacturing platform for antibodies and biosimilars.
- The funding will support the scale-up of the company’s GMP CDMO platform to 50 L and 200 L manufacturing capacity, alongside advancing development programs and strategic partnerships.
SimAbs has raised €5 million in a Series A funding round to expand its continuous manufacturing platform for antibodies and biosimilars. The investment brings together both existing and new strategic investors supporting the company’s biologics manufacturing approach.
The company said the funding will be used to scale its GMP contract development and manufacturing organization (CDMO) platform to 50 L and 200 L manufacturing capacity. SimAbs also plans to advance antibody and biosimilar development programs while building additional strategic partnerships.
SimAbs focuses on continuous manufacturing for biologics production. The company said its platform is designed to enable higher productivity, consistent product quality, and lower cost of goods compared with traditional manufacturing approaches.
The funding will also support commercial expansion as the company seeks to grow its contract manufacturing capabilities and strengthen collaborations with biotechnology partners.
SimAbs said the investment will allow it to scale its antibody manufacturing platform and continue developing technologies intended to support more efficient biologics production.
